ARCHIVES

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

This article is from The Cancer Letter archive.

Vol. 28 No. 35 | September 27, 2002

Download PDF Visit The Full Archive

Related Articles

ACS Board allocated $37.5 Million to Research; More Coming

February 20, 1987

Roche Markets CMV Test in Europe

April 29, 2011

Professional societies: ACCC honors Clinton For Cancer Drug Initiatives, Insurance Bill

September 27, 1996

DCE Advisors Approve New Epidemiology RFPs Table Proposed RFA

April 16, 1993

Klausner To Serve As Advisor On Bioterrorism For NAS.

January 4, 2002

Tucson Conference Could Be Lively

February 16, 1979